Washington Lykkegaard

2 months (95% CI 4.7-10.9) in the AImonotherapy arm (hazard ratio [HR] 0.71, 95% CI 0.47-1.06). Objective response rate was 22.4% in everolimus+AIarm and 19.2% in AImonotherapy arm. A higher proportion of disease progression as best response was reported in the AImonotherapy arm (28.8% versus 14.3%). Median OS was 35.7 months (95% CI 26.0-47.8) in…[Read more]